US-based Alzheon’s Alzheimer’s disease pill has failed in a Phase III trial, but the biopharma still holds hope for the drug ...

Dr. Gonzalo Hidalgo, a Neurologist at Reliant Specialty Infusions, said he believes his clinic is the first in Louisiana to ...

Valiltramiprosate was no better than placebo at slowing cognitive decline, as assessed by ADAS-Cog13, in the latest phase 3 ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Some neurologists and a consumer watchdog worry that an Eli Lilly–affiliated direct-to-consumer telehealth platform for Alzheimer’s could lead to misdiagnosis or unnecessary treatment.

Eli Lilly’s stock has hit a 52-week low at $697.35, nosediving over 10% this past week, which has investors holding their ...

Manufacturers of Alzheimer’s disease drugs have identified blood tests as a way to accelerate diagnosis and treatment.

That's why Veeva Systems should remain a leader in its niche and deliver excellent returns over the long run. It's a top stock to buy and hold for the next two decades.

Jim Cramer in a latest program on CNBC urged investors to start accepting the reality of the new economic system under ...

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...

Biopharma leaders react to the forced resignation of CBER Head Peter Marks as RFK Jr.’s promised job cuts begin at the FDA; ...

Sleep deficiency was associated with atrophy of the inferior parietal region, which is observed in early Alzheimer's disease.